Xenetic Biosciences Inc is a biopharmaceutical company committed to providing innovative solutions in genetic research and drug development. With a focus on improving patient outcomes, Xenetic strives to deliver advanced therapies for a wide range of diseases. The company believes in fostering a culture of collaboration and scientific excellence, working closely with leading experts and leveraging cutting-edge technologies. Xenetic's corporate philosophy emphasizes ethical practices, transparency, and a dedication to creating value for shareholders, employees, and the global healthcare community. By harnessing genetic engineering and biotechnology, Xenetic Biosciences Inc aims to revolutionize medical treatments and shape the future of personalized medicine.

Xenetic Biosciences Inc is primarily present in the United States.

Xenetic Biosciences Inc has achieved several significant milestones in its history. One of the notable achievements of the company was the successful completion of a Phase 2 clinical trial for its lead product candidate, XBIO-101. This drug is being developed for the treatment of progesterone receptor negative (PR-) breast cancer. Another notable milestone for Xenetic Biosciences Inc was the initiation of a Phase 1 study for its proprietary PolyXen platform technology. This technology offers a potential solution for improving drug delivery and enhancing the therapeutic benefit of existing treatments. Overall, Xenetic Biosciences Inc has made substantial progress in its drug development programs, positioning itself as an emerging leader in the biopharmaceutical industry.

Xenetic Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of innovative therapies for rare diseases and oncology. Founded in 2011, Xenetic Biosciences has rapidly gained recognition for its cutting-edge technologies and advancements in biotherapeutics. With a focus on employing its proprietary PolyXen and OncoHist platforms, the company strives to improve the efficacy and safety profiles of existing drugs while also integrating next-generation biotherapeutic candidates into its pipeline. By leveraging its expertise in genetic engineering and protein modification, Xenetic Biosciences Inc aims to transform patient care and address unmet medical needs. This forward-thinking approach positions the company as an industry leader in the field of biotechnology.

The main competitors of Xenetic Biosciences Inc in the market include companies such as BioMarin Pharmaceutical Inc, bluebird bio, Inc, Sangamo Therapeutics, Inc, and Spark Therapeutics, Inc. These companies operate in the biotechnology and pharmaceutical industry and compete with Xenetic Biosciences in developing novel therapies and treatments. In terms of product portfolio and market presence, these competitors pose significant challenges for Xenetic Biosciences as it strives to establish its unique position and gain market share. However, Xenetic Biosciences continues to focus on innovative research and strategic collaborations to differentiate itself from its competitors and provide valuable solutions in the industry.

Xenetic Biosciences Inc primarily operates in the biotechnology industry.

The business model of Xenetic Biosciences Inc revolves around developing and commercializing innovative biopharmaceutical products. The company employs its proprietary technology platform, PolyXen™, to create novel drug candidates with improved therapeutic profiles. Xenetic Biosciences Inc focuses on employing this platform to advance a range of therapeutic products in areas like oncology, immunology, and neurology. By leveraging their expertise in protein engineering, the company aims to generate value for both patients and shareholders through the development and commercialization of differentiated drugs.

Xenetic Biosciences Коефіцієнт P/E становить -3,84.

Коефіцієнт виручки від продажу Xenetic Biosciences становить 2,71.

АлеАкції індекс якості для Xenetic Biosciences складає 3/10.

очікувана Xenetic Biosciences обсяг продажів становить 2,24 млн. USD.

очікувана Xenetic Biosciences прибуток становить -1,59 млн. USD.

Xenetic Biosciences Inc is a company that focuses on the development of biopharmaceuticals and therapies for various diseases and conditions. The business model of Xenetic Biosciences includes research, development, licensing, and marketing of products in various areas such as oncology, neurology, infectious diseases, and blood diseases.

Xenetic Biosciences виплачує дивіденд у розмірі 0 USD, розподілений на виплати протягом року.

Дивіденди для Xenetic Biosciences на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Xenetic Biosciences є US9840155033.

WKN Xenetic Biosciences становить A2PMYU.

Тікер Xenetic Biosciences це XBIO.

Протягом останніх 12 місяців компанія Xenetic Biosciences виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Xenetic Biosciences виплатить дивіденд у розмірі 0 USD.

Дивідендна дохідність Xenetic Biosciences наразі становить .

Xenetic Biosciences виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Xenetic Biosciences протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 USD. Це відповідає дивідендній дохідності 0 %.

Xenetic Biosciences призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Xenetic Biosciences від 17.09.2024 у розмірі 0 USD, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 17.09.2024.

Останню дивіденду було виплачено 17.09.2024.

У 2023 році компанія Xenetic Biosciences виплатила 0 USD у вигляді дивідендів.

Дивіденди Xenetic Biosciences виплачуються у USD.